Positive early clinical results for amivantamab plus lazertinib in NSCLC
Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib
Preclinical research offers promise of new CDK4/6 inhibitors
Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models
Switch maintenance with darolutamide shows promise in previously treated mCRPC
Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study
Does perioperative chemotherapy improve outcomes in PDAC? Evidence is not yet conclusive
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
Possible changes in the standard of care for metastatic and non-metastatic prostate cancer
Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer
KRAS G12C inhibition shows potential for the improved management of advanced CRC
Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials
De-escalated treatment improves the management of stage IIA/B seminoma
Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy
Longer survival benefit with pembrolizumab plus chemotherapy in TNBC
Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease
Early CDK4/6 inhibitors are not inferior to chemotherapy in HR+/HER2- metastatic breast cancer
Seemingly disappointing survival findings in the final results from the PEARL study are balanced by better quality of life with combination therapy
Phase III data highlight the promise of antibody–drug conjugates in metastatic breast cancer
Significant progression-free survival benefits in pre-treated HER2-positive metastatic disease reported in the DESTINY-BREAST03 and SYD985.002/TULIP trials